On Thursday, Tarsus Pharmaceuticals stock reached an important technical milestone, seeing its Relative Strength (RS) Rating jump into the 90-plus percentile with an improvement to 91, up from 84 the day before.
When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength. This unique rating measures technical performance by using a 1 (worst) to 99 (best) score that identifies how a stock's price performance over the trailing 52 weeks matches up against other publicly traded companies.
History shows that the top-performing stocks typically have an RS Rating of above 80 as they begin their biggest climbs.
Looking For Winning Stocks? Try This Simple Routine
Is Tarsus Pharmaceuticals Stock A Buy?
Now is not an ideal time to jump in since it isn't near a proper buy zone, but see if Tarsus Pharmaceuticals stock manages to form a base and break out.
The biotech company showed 0% EPS growth last quarter, while sales growth came in at -100%.
Tarsus Pharmaceuticals holds the No. 140 rank among its peers in the Medical-Biomed/Biotech industry group. Amphastar Pharm, Immunogen and Neurocrine Biosciences are among the top 5 highly rated stocks within the group. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
